In the NEJ026 (Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer) study, the median PFS was 4.3 months longer for patients with pleural effusions treated with erlotinib plus bevacizumab than for those treated with erlotinib alone (16.9 mo versus 12.6 mo).17 This evidence concerns the gene EGFR and Pleural effusion.